Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease
about
TSPO imaging in parkinsonian disordersDevelopment of positron emission tomography β-amyloid plaque imaging agentsEarly AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brainImaging frontotemporal lobar degeneration.Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNIImaging approaches for dementia.Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain.Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease.Noninvasive molecular imaging of neuroinflammationEarly astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography.In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 miceUsing Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's diseaseMolecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 kinase and JNK kinase.Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging InitiativePostmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging.In vivo characterization of the early states of the amyloid-beta network.Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's AssociationAmyloid-β positron emission tomography imaging probes: a critical review.Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targetingCerebral amyloid PET imaging in Alzheimer's disease.Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment.Proteome of brain glia: the molecular basis of diverse glial phenotypes.Imaging of neuroinflammation in parkinsonian syndromes with positron emission tomography.Can insulin signaling pathways be targeted to transport Aβ out of the brain?Fibrillar β-amyloid 1-42 alters cytokine secretion, cholinergic signalling and neuronal differentiation.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Immunomodulatory effects of nicotine on interleukin 1β activated human astrocytes and the role of cyclooxygenase 2 in the underlying mechanism.Biomarkers in Neurodegenerative Diseases.Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.P-Glycoprotein Altered Expression in Alzheimer's Disease: Regional Anatomic Variability.Enzyme-linked immunosorbent assay-based method to quantify the association of small molecules with aggregated amyloid peptides.Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.Detection of brain amyloid β deposition in patients with neuropsychological impairment after traumatic brain injury: PET evaluation using Pittsburgh Compound-B.In vitro binding of [³H]PIB to human amyloid deposits of different types.
P2860
Q26747214-2262FC9F-2BA4-4A88-8081-A897DB9C6245Q27012742-F53CD7B4-8556-49C7-A7EE-681C519D4E89Q30422060-54CEC64E-A2A8-4EFD-A6F0-A0F932308609Q30542245-AF4BA1CE-9264-45B8-9BAD-F16CD355F81EQ30846573-6E1BF866-CB82-4812-BFD5-FC0216E93803Q31110973-E05124AE-6B8A-435A-8065-1A838FAFE88EQ34089121-34855415-22F3-4892-9A02-F9BF724448F8Q35582909-5356C37F-0B45-4006-8E61-3DD86FD12C15Q35599843-9749458C-B998-450C-9EB2-9EE8B2FB873DQ35840623-958F733B-4D75-48C6-B581-C466A5A62CF2Q35905536-71D20A68-7371-4F08-95EE-E74CDEF63392Q36062457-AC85112C-56FC-4027-A62C-BC9B8B8003CCQ36079268-795A504F-B6EC-4E89-A4D9-C787D2D8F6A8Q36265825-1B0E825C-D70F-4677-A8DA-8E142BCCC2D6Q36370083-A1443E17-D627-44CA-B632-A426D971B3BCQ36526176-B7C470EC-B0F6-4E4E-985A-44876722E432Q36615510-C354B077-6752-4878-81F0-5506492D8F58Q36727886-F4330740-5C9A-46B0-B112-FE7DC59796BFQ36889603-6F05C36B-AD6C-41D1-A5FB-ED99749808C0Q36944895-37BCF072-571E-40BE-BE95-34BD2B19411FQ36953870-647A9E7B-1EE7-482C-8CD2-7F360434BC8EQ37069527-483A1498-B922-40B2-A600-E748AAE9C813Q37086266-5DAD407B-5E6C-443E-8AFE-399EF9810F6AQ37126036-D7A37877-7373-4813-8031-F93C142C7324Q37459083-B5C71537-AC86-42DD-A22D-C828AC66FB41Q37498339-2235F615-6BCC-4DFA-8E68-AF9F5B1538CFQ37976853-EF78B288-BA54-4FFA-A61A-EBF5EB4DC969Q38152439-371AA8C4-CC4C-4839-A9E1-2555927C3AFAQ38154242-665D1C98-71D6-49FB-8AF0-5F4425F6B621Q38542045-1850BA72-FA86-49A3-8528-FB1ABAE57250Q38967438-FC9ADC49-E3AA-451F-B71F-3542D9949D65Q38979999-795F8F34-149F-4041-9763-82C43E969E52Q39342494-D2688FE3-F9D9-46F8-B262-F23B7FE7DA1DQ39413097-EAA34558-CB3D-46E3-A235-6319F6A52F86Q39613391-0D1732E4-77DD-49C8-AD35-421B56C36400Q40597133-F059BFF7-4777-4D6C-87BD-27C0CA1258F5Q41039446-ADEBFA11-BE8D-4793-82D9-52D33043F8C9Q43058539-D3A255BF-8063-4CFF-BA03-266B677B2915Q43760143-729F656A-B658-4E6D-A69E-83A0ADCADAE8Q46222348-8AA5EA34-4055-49DE-8154-B90D207E686A
P2860
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Positron emission tomography i ...... tient with Alzheimer's disease
@ast
Positron emission tomography i ...... tient with Alzheimer's disease
@en
type
label
Positron emission tomography i ...... tient with Alzheimer's disease
@ast
Positron emission tomography i ...... tient with Alzheimer's disease
@en
prefLabel
Positron emission tomography i ...... tient with Alzheimer's disease
@ast
Positron emission tomography i ...... tient with Alzheimer's disease
@en
P2093
P2860
P50
P356
P1433
P1476
Positron emission tomography i ...... tient with Alzheimer's disease
@en
P2093
Ahmadul Kadir
Amelia Marutle
Inger Nennesmo
Malahat Mousavi
Tamanna Mustafiz
P2860
P304
P356
10.1093/BRAIN/AWQ349
P407
P577
2010-12-13T00:00:00Z